FY2024 EPS Estimates for OmniAb Raised by Leerink Partnrs

OmniAb, Inc. (NASDAQ:OABI) – Analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for OmniAb in a research note issued to investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of ($0.59) for the year, up from their prior estimate of ($0.62). The consensus estimate for OmniAb’s current full-year earnings is ($0.62) per share.

A number of other equities research analysts also recently weighed in on the company. Benchmark restated a “buy” rating and set a $8.00 target price on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Trading Down 1.9 %

Shares of NASDAQ OABI opened at $3.57 on Thursday. OmniAb has a 1-year low of $3.43 and a 1-year high of $6.72. The company has a 50-day moving average of $3.90 and a two-hundred day moving average of $4.10. The company has a market cap of $504.14 million, a PE ratio of -5.76 and a beta of -0.10.

Hedge Funds Weigh In On OmniAb

Several institutional investors and hedge funds have recently modified their holdings of OABI. CWC Advisors LLC. bought a new stake in shares of OmniAb in the third quarter valued at about $54,000. Walleye Capital LLC acquired a new stake in shares of OmniAb in the third quarter valued at about $61,000. Intech Investment Management LLC acquired a new position in OmniAb during the third quarter valued at approximately $70,000. China Universal Asset Management Co. Ltd. increased its position in shares of OmniAb by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock worth $96,000 after purchasing an additional 8,909 shares during the last quarter. Finally, Palumbo Wealth Management LLC grew its stake in OmniAb by 12.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after buying an additional 2,744 shares during the last quarter. 72.08% of the stock is currently owned by institutional investors and hedge funds.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.